[1]
|
罗子怡, 周芙玲. 2019年美国国立综合癌症网多发性骨髓瘤诊治的指南更新解读[J]. 临床内科杂志, 2020, 37(1): 71-72.
|
[2]
|
Banerjee, S.S., Verma, S. and Shanks, J.H. (2004) Morphological Variants of Plasma Cell Tumours. Histopathology, 44, 2-8. https://doi.org/10.1111/j.1365-2559.2004.01763.x
|
[3]
|
Greipp, P.R., Raymond, N.M., Kyle, R.A., et al. (1985) Multiple Myeloma: Significance of Plasmablastic Subtype in Morphological Classification. Blood, 65, 305-310. https://doi.org/10.1182/blood.V65.2.305.305
|
[4]
|
Shivlal, P. and Kyle, R.A. (2013) Unusual Myelomas: A Review of IgD and IgE Variants. Oncology (Williston Park, N. Y.), 27, 798-803.
|
[5]
|
张磊, 刘会兰, 郑昌成, 朱小玉, 汤宝林, 耿良权, 吴竞生, 朱薇波, 刘欣, 郑辉, 孙自敏. 17例IgD型多发性骨髓瘤临床分析[J]. 临床血液学杂志, 2015, 28(1): 12-15+18.
|
[6]
|
安然, 何海燕, 姜华, 李璐, 赵云阳, 吴昊, 贺婕, 张慧, 侯健. 130例IgD型多发性骨髓瘤临床特点及预后分析[J]. 临床血液学杂志, 2017, 30(3): 194-197.
|
[7]
|
Liu, J., Hu, X., Jia, Y., et al. (2020) Clinical Features and Survival Outcomes in IgD Myeloma: A Study by Asia Myeloma Network (AMN). Leukemia. https://doi.org/10.1038/s41375-020-01060-w
|
[8]
|
Shimamoto, Y., Anami, Y. and Yamaguchi, M. (1991) A New Risk Grouping for IgD Myeloma Based on Analysis of 165 Japanese Patients. European Journal of Haematology, 47, 262-267.
https://doi.org/10.1111/j.1600-0609.1991.tb01569.x
|
[9]
|
Liao Arter, Z.H., Miles, D., Mignano, S., et al. (2020) Plasmablastic IgM Multiple Myeloma with Hypocellular Bone Marrow. Annals of Hematology, 99, 895-896. https://doi.org/10.1007/s00277-020-03959-x
|
[10]
|
Zagouri, F., Kastritis, E., Symeonidis, A.S., Giannakoulas, N., et al. (2014) Dimopoulos. Immunoglobulin D Myeloma: Clinical Features and Outcome in the Era of Novel Agents. European Journal of Haematology, 92, 308-312.
https://doi.org/10.1111/ejh.12255
|
[11]
|
Bartl, R., Frisch, B., Burkhardt R., Fateh-Moghadam, A., et al. (1982) Bone Marrow Histology in Myeloma: Its Importance in Diagnosis, Prognosis, Classification and Staging. British Journal of Haematology, 51, 361-375.
https://doi.org/10.1111/j.1365-2141.1982.tb02791.x
|
[12]
|
Sailer, M., Vykoupil, K.F., Peest, D., et al. (1995) Prognostic Relevance of a Histologic Classification System Applied in Bone Marrow Biopsies from Patients with Multiple Myeloma: A Histopathological Evaluation of Biopsies from 153 Untreated Patients. European Journal of Haematology, 54, 137-146.
https://doi.org/10.1111/j.1600-0609.1995.tb00204.x
|
[13]
|
Giampaolo, T., Federica, C., Maurizio, Z., et al. (2006) Clinical and Biological Features of Multiple Myeloma Involving the Gastrointestinal System. Haematologica, 91, 964-967.
|
[14]
|
Joan, B., de Larrea Carlos, F., Laura, R., et al. (2011) Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 3805-3812. https://doi.org/10.1200/JCO.2011.34.9290
|
[15]
|
Greipp, P.R., Leong, T., Bennett, J.M., et al. (1998) Plasmablastic Morphology—An Independent Prognostic Factor with Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group. Blood, 91, 2501-2507. https://doi.org/10.1182/blood.V91.7.2501
|
[16]
|
Kaibara, H., Kaida, H., Ishibashi, M., et al. (2009) 18 F-FDG-PET Findings of Rare Case of Nonsecretory Plasmablastic Myeloma. Annals of Nuclear Medicine, 23, 807-811. https://doi.org/10.1007/s12149-009-0300-2
|
[17]
|
Møller, H.E.H., Preiss, B.S., Pedersen, P., et al. (2015) Clinicopathological Features of Plasmablastic Multiple Myeloma: A Population-Based Cohort. APMIS, 123, 652-658. https://doi.org/10.1111/apm.12411
|
[18]
|
Shmuel, Y. (2005) The Phenotypic Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature, Resilient, and Apoptosis-Resistant Phenotype. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 11, 7599-7606. https://doi.org/10.1158/1078-0432.CCR-05-0523
|
[19]
|
Fakhri, B. and Vij, R. (2016) Clonal Evolution in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 16, S130-S134. https://doi.org/10.1016/j.clml.2016.02.025
|
[20]
|
邱荃, 朱平, 王茫桔, 等. 初诊多发性骨髓瘤患者CD56和CD19表达与染色本核型及预后的关系[J]. 中国实验血液学杂志, 2016, 24(4): 1071-1078.
|
[21]
|
Swerdlow, S.H., Campo, E., Harris, N.L., et al. (2008) WHO Classification of Tumors. In: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 256-257.
|
[22]
|
Shenon, S. and Ira, M. (2016) Plasma Cell Myeloma with Anaplastic Transformation. Blood, 128, 2106.
https://doi.org/10.1182/blood-2016-08-731844
|
[23]
|
Ribourtout, B. and Zandecki, M. (2015) Plasma Cell Morphology in Multiple Myeloma and Related Disorders. Morphologie, 99, 38-62. https://doi.org/10.1016/j.morpho.2015.02.001
|
[24]
|
Rajkumar, S.V., Fonseca, R., Lacy, M.Q., et al. (1999) Plasmablastic Morphology Is an Independent Predictor of Poor Survival after Autologous Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 17, 1551-1557. https://doi.org/10.1200/JCO.1999.17.5.1551
|
[25]
|
Licci, S. (2017) Duodenal Localization of Plasmablastic Myeloma. World Journal of Gastrointestinal Pathophysiology, 8, 93-95. https://doi.org/10.4291/wjgp.v8.i2.93
|
[26]
|
Reddy, R., Vohra, S. and Macurak, R. (2015) Secondary Extramedullary Plasmablastic Myeloma of the Small Bowel. Clinical Gastroenterology and Hepatology, 13, A23-A24. https://doi.org/10.1016/j.cgh.2015.06.029
|
[27]
|
Castillo, J.J., Guerrero-Garcia, T., Baldini, F., et al. (2019) Bortezomib plus EPOCH Is Effective as Frontline Treatment in Patients with Plasmablastic Lymphoma. British Journal of Haematology, 184, 679-682.
https://doi.org/10.1111/bjh.15156
|